Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Ranbaxy Inc.
ClinicalTrials.gov Identifier:
NCT00775827
First received: October 17, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose crossover bioavailability study on fenofibrate formulations comparing fenofibrate 160 mg tablets of Ranbaxy Laboratories with Tricor 160 mg tablets in healthy, adult, human subjects under fasting conditions.


Condition Intervention
Healthy
Drug: fenofibrate 160 mg tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Fenofibrate Formulations Comparing Fenofibrate 160 mg Tablets of Ranbaxy Laboratories With Tricor 160 mg Tablets of in Healthy, Adult, Human Subjects Under Fasting Conditions

Resource links provided by NLM:


Further study details as provided by Ranbaxy Inc.:

Primary Outcome Measures:
  • Bioequivalence [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: November 2002
Study Completion Date: December 2002
Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
fenofibrate 160 mg tablets of Ranbaxy Laboratories
Drug: fenofibrate 160 mg tablets
Active Comparator: 2
Tricor 160 mg tablets
Drug: fenofibrate 160 mg tablets

Detailed Description:

This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 40 healthy adult male subjects.

As per protocol, enough healthy, adult, human subjects were to be enrolled in the study to allow the dosing of 40 subjects in the first period. 40 subjects were enrolled and a total of 37 subjects completed both the periods of study.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be in the age range of 18-45 years.
  • Be neither overweight nor underweight for his/her height as per te Life insurance Corporation of india height/weight chart for non-medical cases.
  • Have voluntarily given written informed consent to participate in this study.

Be of normal health as determined by medical history and physical examination of the subjects performed within 28 days prior to the commencement of the study.

If female and:

Of childbearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or TS postmenopausal for at least 1 year; or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion Criteria:

History of allergy to fenofibrate and related fibric acid derivatives.

  • History of gall stones/cholecystitis
  • Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
  • Presence of disease markers of H~-I and 2, Hepatitis B and C viruses and syphilis infection.

Female volunteers demonstrating a positive pregnancy screen.

Female volunteers who are currently breasffeeding.

  • Presence of values which are clinically significantly different from normal reference ranges (as defined in Appendix 5) for haemoglobin, total white blood cells count, differential WBC count and platelet count.
  • Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids)
  • Presence of values which are significantly different from normal reference ranges (as defined in Appendix 5) for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose, serum cholesterol and serum triglycerides.

Clinically abnormal chemical and microscopic examination of urine defined as presence .of RBC, WBC (>4/HPF), epithelial cells (>4/HPF), glucose (positive) and protein (positive).

Clinically abnormal ECG and Chest X-ray.

  • History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma.
  • History of any psychiatric illness which may impair the ability to provide written informed consent.
  • Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
  • History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (! Unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the'duration of each study period.

Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.

Participation in any clinical trial within 6 weeks preceding Day ! of this study.

  • Subjects who, through completion of this study, would have donated and/or lost more than 35;0 mL of blood in the past 3 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00775827

Locations
India
Ranbaxy Research Laboratories
Gurgaon, Haryana, India
Sponsors and Collaborators
Ranbaxy Laboratories Limited
  More Information

Additional Information:
No publications provided

Responsible Party: Dr. Tausif Monif, Ranbaxy Research Laboratories
ClinicalTrials.gov Identifier: NCT00775827     History of Changes
Other Study ID Numbers: 028/FENOF-160/02
Study First Received: October 17, 2008
Last Updated: October 17, 2008
Health Authority: India: Drugs Controller General of India

Keywords provided by Ranbaxy Inc.:
bioequivalence fenofibrate tablets

Additional relevant MeSH terms:
Fenofibrate
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 17, 2014